Omeros Corporation — FY2023 Form 10-K
Reporting period: Year ended December 31, 2023; filed April 1, 2024. Omeros is a clinical-stage biopharmaceutical company focused on complement-related diseases and other programs. It sold OMIDRIA in 2021 and now relies primarily on financing and legacy OMIDRIA royalty-related proceeds rather than product sales.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue from continuing operations | No product revenue reported | No product revenue reported |
| Research and development expense | $114.9 million | $112.7 million |
| Selling, general and administrative expense | $49.7 million | $50.7 million |
| Loss from continuing operations | $174.9 million | $182.0 million |
| Net income (loss) | $(117.8) million | $47.4 million |
| Net income from discontinued operations | $57.1 million | $229.4 million |
| Cash provided by (used in) operating activities | $74.7 million | $(86.5) million |
- Year-end cash, cash equivalents and short-term investments were $171.8 million, versus $194.9 million at December 31, 2022. The filing says the company expects existing resources, including $115.5 million received from DRI in February 2024, to fund operations for at least the next 12 months.
- Operating cash flow was positive in 2023 mainly because Omeros collected the $200 million OMIDRIA milestone payment from Rayner. It should not be read as evidence that continuing operations generate recurring cash.
- At year-end, 2026 convertible notes had $215.9 million principal outstanding and a $213.2 million net carrying amount; they bear 5.25% interest and mature February 15, 2026. The company also reported a $125.1 million OMIDRIA royalty obligation and approximately $1.3 million of finance lease obligations.
- Interest expense rose to $30.8 million from $22.7 million, primarily because the DRI royalty obligation incurred interest for a full year. No operating margin is presented; the company reported an operating loss.
Material changes versus the prior year
- Net results shifted from $47.4 million income in 2022 to a $117.8 million loss in 2023, largely because 2022 included $200 million of OMIDRIA milestone income. Discontinued-operations income fell to $57.1 million from $229.4 million.
- Continuing-operations loss narrowed by $7.1 million. R&D expense increased $2.1 million, with higher OMS906 and OMS1029 spending partly offset by lower narsoplimab costs; SG&A decreased $1.0 million.
- Rayner’s U.S. OMIDRIA sales rose to $135.3 million from $130.9 million, but Omeros’s royalty earnings declined to $40.6 million from $65.4 million after its U.S. royalty rate fell from 50% to 30% upon achievement of the milestone event.
- Omeros repurchased 1.8 million shares for $4.7 million during 2023. In December, it repurchased $9.1 million principal of 2026 notes at a discount, recording a $4.1 million non-cash gain. The $95 million 2023 notes matured and were repaid in November.
Outlook, commentary and key risks
- Narsoplimab / TA-TMA: FDA previously issued a complete response letter. Omeros submitted an analysis plan in fall 2023 and continues discussions with FDA; the company cannot estimate when it will resubmit the BLA or whether approval will follow. An EMA application is expected after BLA resubmission.
- OMS906: Phase 2 programs are underway in PNH and C3G. Omeros targets PNH Phase 3 trials in late 2024 and C3G Phase 3 development in early 2025, subject to data and regulatory discussions.
- Other programs: OMS1029 Phase 1 follow-up was ongoing, with study completion expected in mid-2024. Narsoplimab’s Phase 3 IgA nephropathy trial was discontinued after failing to reach statistical significance on its primary endpoint.
- Management expects 2024 R&D expense to be similar to 2023. SG&A could increase if narsoplimab is approved and launch preparations begin, or decrease if it is not approved.
- The February 2024 DRI amendment provided $115.5 million upfront in exchange for all U.S. OMIDRIA royalties payable from 2024 through 2031. Omeros may also receive two sales-based milestone payments of up to $27.5 million each; their achievement is uncertain. Omeros retains specified ex-U.S. royalties and royalties after 2031.
- Key risks include continued losses and potential need for additional capital, the 2026 note maturity, regulatory and clinical uncertainty, dependence on third-party manufacturers, reimbursement and competitive pressures, and the uncertain value and timing of OMIDRIA-related proceeds. The company has a $150 million at-the-market equity facility and may pursue other financing or reduce spending.
- No material legal proceedings were reported. The auditor issued an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting, and the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Cash runway assumptions, projected operating spend, and the company’s ability to address the February 2026 convertible-note maturity without substantial dilution or asset monetization.
- FDA’s feedback on the narsoplimab analysis plan, the timing and scope of any TA-TMA BLA resubmission, and the likelihood of approval.
- OMS906 Phase 2 results, dose selection, and whether planned PNH and C3G Phase 3 timelines remain achievable.
- Rayner’s OMIDRIA sales, the resulting royalties and any sales thresholds for DRI milestone payments, together with the accounting estimates underlying the royalty asset.
- Potential dilution from the at-the-market facility, outstanding options and convertible notes, and the effect of the share repurchase program on liquidity.